Tirzepatide Ups Mean Weight Loss by 21% Following Intensive Lifestyle Intervention: SURMOUNT-3
Tirzepatide could help individuals who lose weight with lifestyle change to maintain and augment that loss, a well known challenge among persons with obesity.
FDA Accepts sBLA for Self-Administered Intranasal Influenza Vaccine from AstraZeneca
The flexibility to self administer a flu vaccine or to administer to another in a non-clinical setting could greatly expand both access and vaccine uptake.
Combination Influenza/COVID-19 Vaccine Enters Phase 3 Trial, First Participant Dosed
The investigational combination vaccine against influenza and SARS-CoV-2 proved both safe and effective in recent results from a phase 1/2 trial, said Moderna.
FDA Approves Pentavalent Meningococcal Vaccine from Pfizer for Ages 10 to 25 years
The Pfizer product is the first vaccine indicated to prevent the 5 most common serogroups causing meningococcal disease in adolescents and young adults.
Next Generation Cologuard Outperforms FIT for CRC Detection, Shows Improved Sensitivity, Specificity
A pivotal phase 3 clinical trial showed Cologuard significantly more likely than FIT to detect cancerous and advanced precancerous lesions.
10 Top Studies from IDWeek for Primary Care, In Case you Missed Them
IDWeek was packed with so much new science it was hard to make choices. Here we topline 10 with outcomes of interest to primary care, ICYMI.
New Data on Alzheimer Disease Research from Biogen Planned for Release at CTAD 2023 Meeting
At the Clinical Trials on Alzheimer's Disease Meeting, October 24-28, the biotech company will update research on lecanemab, aducanumab, and an early-stage disease treatment.
Obesity, Severe Obesity Increase Risk for Breast Cancer Recurrence
In postmenopausal women with HR+ breast cancer who had obesity, recurrence of breast cancer while on aromatase inhibitor therapy was 18%, report investigators.
AHA Defines Cardiovascular-Kidney-Metabolic Syndrome, Redefines CVD Risk, Prevention, Management
A new paradigm for reducing CV morbidity and mortality provides a comprehensive approach to comorbid metabolic disease including early detection and treatment.
Obesity Before, During Pregnancy Key to Future Cardiovascular Risk, New Research Suggests
A novel study strongly suggests that pre-pregnancy obesity rather than associated adverse pregnancy outcomes is the "culprit" in postpartum heart disease.
FDA Issues Marketing Denial Orders for 6 Vuse Alto Flavored e-Cigarette Products
The FDA cites insufficient evidence to show the products would be beneficial for adults switching to vaping from combustible tobacco products or quitting.
IDWeek 2023 Chair on Primary Care: "Central to Every Health Outcome We Have in the US..."
IDWeek chair Heather Yun, MD, observed that "primary care clinicians are out in front of all things," and that job is big and it's hard.
GLP-1 Mimetic Semaglutide Is Effective Across Ejection Fraction in Patients with HFpEF and Obesity: New STEP-HFpEF Analysis
Semaglutide treatment reduced weight and was associated with greater, more consistent improvements in HFpEF than other recently studied drug classes.
Heather Yun, MD, IDWeek 2023 Chair, Says Emerging Threats May be Bigger than Pathogens
IDWeek 2023 chair Yun points to climate change and other human-driven devastation of the biosphere as the global threats that will cause disease at local levels.
IDWeek 2023: Nirsevimab Efficacy Against RSV-LRTI-Associated Hospitalization is Robust Across Infant Subgroups
IDWeek 2023. Nirsevimab efficacy was significant across infant subgroups in preventing hospitalization for RSV-LRTI during a first RSV season.
IDWeek 2023: Social Determinants of RSV Hospitalization in Older Adults
IDWeek 2023: Older adults hospitalized with respiratory syncytial virus were more likely to be women, be immunocompromised, and to have traveled within the prior 2 weeks,
Investigational mRNA CMV Vaccine Ready for Phase 3 Clinical Trial, Based on Results of Phase 2 Safety, Efficacy and Dose-Finding Study
The phase 2 study found that nAB responses against epithelial cell infection were strong after each mRNA-1647 dose and sustained through 12 months.
IDWeek 2023 Late Breaker: Efficacy of Single RSVPreF3 Dose Sustained Over 2 Seasons in High-Risk Older Adults
A phase 3 study found VE from a single shot against RSV-LRTD in adults aged ≥60 years persisted through a second season; revaccination did not increase protection.
Pfizer Maternal RSV Vaccine Could Reduce Infant Clinical Events by Tens of Thousands, Costs by $800 Million
A modeling study projected an annual reduction of nearly 25 000 infant hospitalizations and 46 000 ED encounters following maternal vaccination against RSV.
Coadministration of RSV, Influenza Vaccines is Safe and Effective in Older Adults, Study Finds
Immune response in older adults after receiving both vaccines in the same visit was noninferior to sequential administration and the safety profile was acceptable.
Late-Breaker: COVID-19 mRNA-1273 Booster Most Effective Among Adults Aged 65 and Older During Delta, Omicron Surges
The study findings on enhanced immunity from a third mRNA-1273 dose and specific population benefits will help build effective public health policy, authors say.
Breaking: Novel Live-Attenuated Intranasal COVID-19 Vaccine Yields Significant Humoral, Cellular Immune Response
The intranasal delivery and live attenuated form of CoviLiv may strengthen immune response and vaccine acceptance and uptake in populations and regions where both are low.
Novo Stops Semaglutide Kidney Outcomes Trial Early for Efficacy
The phase 3 semaglutide kidney outcomes trial will be stopped immediately with FLOW read out expected in early 2024, the company said.
In People Living with HIV, Switch from Oral ART to Long-Acting Injectable Significantly Improved Adherence, Persistence
IDWeek 2023: In a large cohort of people living with HIV, those switching from oral ART to long acting CAB+RPV were more than 4x as likely to adhere to the regimen.
Real-World Study Finds Long-Acting Cabotegravir+Rilpivirine Highly Effective in Persons with HIV with Detectable Viral Loads at Treatment Inititiaton
Approved for persons with HIV with undetectable VL, CAB+RPV LA may also be appropriate for those with VL ≥50 copies when the therapy is initiated, according to new findings.
IDWeek 2023: Tripledemic Viruses Under the Microscope
COVID-19, influenza, and RSV will be the topics of a different types of sessions examining the history, new diagnostics, prevention, and future treatments during IDWeek 2023.
IDWeek 2023 Features Leaders Spanning the Specialty's Expertise
IDWeek 2023: Leading physician scientists will headline plenary sessions and named lectureships on topics ranging from antibiotic stewardship to artificial intelligence.
How to Get Shots into Arms this Year: Patience, Persistence, and Don't Take it Personally
AAFP president-elect Steven Furr, MD, offers 3 thoughts on maximizing opportunities this year to give all necessary vaccines.
IDWeek 2023, October 11-15: Preview of Topics and Presentations
IDWeek 2023: Imagine an intriguing hot topic in infectious disease and you'll find a session or 2 where you can learn more and then choose the next topic, rinse, and repeat.
AAFP President-Elect Welcomes the Simplicity of the Seasonal COVID-19 Vaccine
The monovalent, singe-shot COVID-19 vaccine simplifies what used to be a complicated conversation with patients and stocking the vaccine fridge, too, says Steven Furr, MD.